Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Tineke Casneuf"'
Autor:
Justin Cha, Cody J. Boehner, Nikhil C. Munshi, Romanos Sklavenitis-Pistofidis, Kwee Yong, Chip Stewart, Karma Salem, Eliezer M. Van Allen, Jihye Park, Yu-Tzu Tai, Andrew Dunford, Shankara Anand, Lorenzo Trippa, Amaro Taylor-Weiner, Jacob P. Laubach, Mark Bustoros, Benny Zhitomirsky, Robert A. Redd, Selina J Chavda, Irene M. Ghobrial, Shaji Kumar, Paul G. Richardson, Kenneth C. Anderson, François Aguet, Tarek H. Mouhieddine, P. Leif Bergsagel, Gad Getz, Mahshid Rahmat, Tineke Casneuf, Meletios A. Dimopoulos, Liudmila Elagina, Carl Jannes Neuse, Salomon Manier, Elizabeth A. Morgan, Ignaty Leshchiner, Efstathis Kastritis
Publikováno v:
J Clin Oncol
PURPOSE Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for risk stratification; however, those are based on solely clinical metrics. The disco
Autor:
Markus Munder, Katja Weisel, Ho Jin Shin, Cindy Lee, Tomer M Mark, Tamás Masszi, Maria-Victoria Mateos, Meral Beksac, Andrew Spencer, Birgitta Lauri, Paolo Corradini, Je-Jung Lee, Asher Chanan-Khan, Tineke Casneuf, Hang Quach, Suzanne Lentzsch, Roberto Ovilla, Jon Ukropec, Jae Cheol Jo, Noemi Horvath, Wolney Barreto, Mark-David Levin, Himal Amin, Marcelo Capra, Ivan Spicka, Pieter Sonneveld, Nikki A. Deangelis, Vania Hungria, Chang-Ki Min, Michele Cavo, Alberto Bosi, Ajay K. Nooka, Hervé Avet-Loiseau, Rachel Kobos
Publikováno v:
Journal of Hematology and Oncology, 13(1):115. BioMed Central Ltd.
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-11 (2020)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-11 (2020)
Digital.CSIC. Repositorio Institucional del CSIC
instname
© The Author(s).
Background: Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd
Background: Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e453fd3c5957c7c092b4ad432fbeacf
https://pure.eur.nl/en/publications/4a3ae139-d91b-4ec7-aede-2cccbadac76d
https://pure.eur.nl/en/publications/4a3ae139-d91b-4ec7-aede-2cccbadac76d
Autor:
Andrew, Spencer, Suzanne, Lentzsch, Katja, Weisel, Hervé, Avet-Loiseau, Tomer M, Mark, Ivan, Spicka, Tamas, Masszi, Birgitta, Lauri, Mark-David, Levin, Alberto, Bosi, Vania, Hungria, Michele, Cavo, Je-Jung, Lee, Ajay K, Nooka, Hang, Quach, Cindy, Lee, Wolney, Barreto, Paolo, Corradini, Chang-Ki, Min, Emma C, Scott, Asher A, Chanan-Khan, Noemi, Horvath, Marcelo, Capra, Meral, Beksac, Roberto, Ovilla, Jae-Cheol, Jo, Ho-Jin, Shin, Pieter, Sonneveld, David, Soong, Tineke, Casneuf, Christopher, Chiu, Himal, Amin, Ming, Qi, Piruntha, Thiyagarajah, A Kate, Sasser, Jordan M, Schecter, Maria-Victoria, Mateos
Publikováno v:
Haematologica
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or
Autor:
Philippe Moreau, Nizar J. Bahlis, Jesús F. San-Miguel, Kihyun Kim, Kaida Wu, Shinsuke Iida, Gordon Cook, Hervé Avet-Loiseau, Nushmia Z. Khokhar, Ajai Chari, A. Kate Sasser, Andrew Belch, Naoki Takezako, Jonathan L. Kaufman, Lisa O'Rourke, H. Miles Prince, Christopher Chiu, Lotfi Benboubker, Marc Lalancette, Saad Z. Usmani, Jordan M. Schecter, P. Joy Ho, James Morton, Jin Seok Kim, Heather J. Sutherland, Darrell White, Tara Cochrane, Albert Oriol, Tineke Casneuf, Meletios A. Dimopoulos, Hila Magen, David Soong, Merav Leiba
Publikováno v:
Haematologica
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow-up and include
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e1d9f1ec1e0b3824ac7004150f04151
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5344
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5344
Autor:
Pierre W. Wijermans, Hong Xie, Peter M. Voorhees, Richard C. Frank, Robert Z. Orlowski, Brett Hall, Britte Kranenburg, Helgi van de Velde, Amrita Krishnan, Xiang Qin, Sonja Zweegman, Robert F. Manges, Sundar Jagannath, George Somlo, Tineke Casneuf, Suzanne Lentzsch, Sheeba K. Thomas, Pieter Sonneveld
Publikováno v:
British Journal of Haematology, 161(3), 357-366. Wiley-Blackwell Publishing Ltd
British Journal of Haematology, 161(3), 357-366. Wiley-Blackwell
Voorhees, P M, Manges, R F, Sonneveld, P, Jagannath, S, Somlo, G, Krishnan, A, Lentzsch, S, Frank, R C, Zweegman, S, Wijermans, P W, Orlowski, R Z, Kranenburg, B, Hall, B, Casneuf, T, Qin, X, te Velde, H, Xie, H & Thomas, S K 2013, ' A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma ', British Journal of Haematology, vol. 161, no. 3, pp. 357-366 . https://doi.org/10.1111/bjh.12266
British Journal of Haematology, 161(3), 357-366. Wiley-Blackwell
Voorhees, P M, Manges, R F, Sonneveld, P, Jagannath, S, Somlo, G, Krishnan, A, Lentzsch, S, Frank, R C, Zweegman, S, Wijermans, P W, Orlowski, R Z, Kranenburg, B, Hall, B, Casneuf, T, Qin, X, te Velde, H, Xie, H & Thomas, S K 2013, ' A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma ', British Journal of Haematology, vol. 161, no. 3, pp. 357-366 . https://doi.org/10.1111/bjh.12266
Interleukin-6 (IL6) plays a central role in multiple myeloma pathogenesis and confers resistance to corticosteroid-induced apoptosis. We therefore evaluated the efficacy and safety of siltuximab, an anti-IL6 monoclonal antibody, alone and in combinat